^
Association details:
| Biomarker: | ERCC1 N118N |
|---|---|
| Cancer: | Osteosarcoma |
| Drug: | cisplatin (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients
Excerpt:
Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….We only observed a tendency towards an increased risk of poor tumor response and reduced EFS in patients carriers of the polymorphic alleles for ERCC1 Lys504Gln and ERCC1 Asn118Asn polymorphisms.
DOI:
10.1038/tpj.2009.19
